**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 65990

**Manuscript Type:** REVIEW

**Role of hospitalization for inflammatory bowel disease in the post-biologic era**

Soriano CR *et al*. IBD hospitalizations during post-biologic era

Celine R Soriano, Charleston R Powell, Michael V Chiorean, Vlad V Simianu

**Celine R Soriano, Vlad V Simianu,** Department of Surgery, Virginia Mason Franciscan Health, Seattle, WA 98101, United States

**Charleston R Powell,** Department of Internal Medicine, Madigan Army Medical Center, Tacoma, WA 98431, United States

**Michael V Chiorean,** Department of Gastroenterology, Swedish Medical Center, Seattle, WA 98109, United States

**Author contributions:** Soriano CR and Simianu VV contributed to the concept of the review; Soriano CR and Powell CR performed the literature review; Soriano CR and Powell CR contributed to manuscript preparation and draft; Soriano CR, Powell CR, Chiorean MV and Simianu VV contributed edits and revisions to the manuscript; all authors have read and approved the final manuscript.

**Corresponding author: Vlad V Simianu, MD, Surgeon,** Department of Surgery, Virginia Mason Franciscan Health, 1100 9th Ave, C6-GS, Seattle, WA 98101, United States. val.simianu@virginiamason.org

**Received:** March 19, 2021

**Revised:** May 17, 2021

**Accepted:** August 12, 2021

**Published online:** September 16, 2021

**Abstract**

Treatment for inflammatory bowel disease (IBD) often requires specialized care. While much of IBD care has shifted to the outpatient setting, hospitalizations remain a major site of healthcare utilization and a sizable proportion of patients with inflammatory bowel disease require hospitalization or surgery during their lifetime. In this review, we approach IBD care from the population-level with a specific focus on hospitalization for IBD, including the shifts from inpatient to outpatient care, the balance of emergency and elective hospitalizations, regionalization of specialty IBD care, and contribution of surgery and endoscopy to hospitalized care.

**Key Words:** Inflammatory bowel disease; Hospitalization; Elective; Emergent surgery; Endoscopy

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Soriano CR, Powell CR, Chiorean MV, Simianu VV. Role of hospitalization for inflammatory bowel disease in the post-biologic era. *World J Clin Cases* 2021; 9(26): 7632-7642

URL: https://www.wjgnet.com/2307-8960/full/v9/i26/7632.htm

DOI: https://dx.doi.org/10.12998/wjcc.v9.i26.7632

**Core Tip:** inflammatory bowel disease (IBD)-related hospitalizations are costly and have increased despite the introduction of advanced therapeutic agents. Over the past few decades, utilization of endoscopy and emergency surgery during hospital admissions have decreased, with a concomitant rise in elective bowel resections. With increased complexity of inpatient and outpatient management of IBD, improved care delivery and outcomes may consist of multidisciplinary teams led by IBD specialists, regionalization, and IBD-specific treatment plans.

**INTRODUCTION**

Crohn’s disease (CD) and ulcerative colitis (UC), collectively termed inflammatory bowel disease (IBD), are chronic, relapsing and remitting conditions that contribute significantly to the public health and economic burden worldwide. The incidence of IBD ranges from 5.0-24.3 per 100000 people globally, and the prevalence is expected to continue to rise given more patients being diagnosed at a young age and the low mortality associated with the disease[1,2].

One of the most important advances in the treatment of IBD over the past several decades is the introduction of biologics. The first clinical trial studied anti-TNF-α therapy for patients with CD where short term efficacy of biologics were established with increased clinical response and remission rates compared to placebo[3]. Further randomized control studies were promising showing increased remission rates at over one year[4]. Subsequent trials were conducted evaluating the efficacy of infliximab in UC, also showing improved clinical response and remission compared to placebo[5]. Given the success and mainstream acceptance of biologics for both induction and maintenance for IBD, a reasonable hypothesis would be that superior disease control would result in a decreased need for hospitalizations and surgery.

Despite the fact that the medical treatment has improved significantly after the introduction of biological drugs, recent studies have shown variable trends in rates of hospital admissions[6–8]. While the IBD patient population is heterogenous and may have an expected course of disease, the need for inpatient medical or surgical care may act as a surrogate for disease severity and failure of outpatient medical treatment or complications thereof. As such, the healthcare burden, population level impact, and drivers of IBD hospitalizations in the current, so-termed “post-biologic era” are important to understand. In this paper, the determinants of cost, utilization, and outcomes of hospital care in patients with inflammatory bowel disease are reviewed.

**impact of hospitalization on healthcare burden**

IBD patients have high healthcare utilization as evident by increased readmission rates, longer length of stay, and increased costs[9,10]. Total and incremental lifetime healthcare costs incurred by patients with CD and UC are much higher than patients with other chronic diseases, and the estimated lifetime cost burden for patients with CD and UC are expected to be $498 billion and $377 billion, respectively.[11] Hospitalizations are an important contributor of total lifetime costs, with $1 in $4 spent on inpatient services for both CD and UC[11,12]. Furthermore, approximately one-fourth of patients with IBD are admitted to the hospital within the first two years of diagnosis[13].

Most patients are initiated on medical management for IBD, tailored to disease activity, location, behavior, extraintestinal manifestations and will often require lifelong therapy. Especially with acute presentations or hospitalization for IBD, systemic corticosteroids are one of the oldest remedies still used today[14–17]. However, steroids have been associated with significant risks including serious and opportunistic infections as well as mortality in patients with IBD and therefore their long-term use has been discouraged in recent guidelines[18,19]. There has been a concomitant shift towards early use of biologics and other therapeutic agents for both CD and UC. Additionally, there has been a movement of healthcare costs from hospitalization and surgery towards anti-TNF therapy, with a Dutch study suggesting anti-TNF-α medications account for 64% and 31% of total costs for CD and UC respectively[20].

Length of stay is also an important measurement of costs and healthcare burden. Extended length of stay is associated with higher hospitalization costs, and hospitalizations related to disease severity are longer in duration than non-IBD causes[12,21,22]. Furthermore, IBD patients requiring critical needs have longer intensive care unit stays than non-IBD patients[23,24]. Factors predisposing IBD patients to increased hospitalization days include immunosuppression, malnutrition, increased risk of Clostridium difficile, and need for interventions, such as gastrointestinal endoscopy or abdominal surgery[24–26].

**Drivers of hospitalization in the contemporary era**

Despite the introduction of advanced therapeutics, hospitalizations remain high, and variable among countries. For instance, a meta-analyses found significant variability in hospitalization rates in 9 European countries, but stable, age-adjusted rates, with a large peak in younger CD patients followed by a smaller peak in elderly patients, and a small peak in younger UC patients followed by a larger peak in elderly patients[27]. It is at odds, therefore, that with what is believed to be increasingly more effective medical therapy, hospitalization rates are stable or increasing[28–30]. Biologics and immunosuppressants are expected to reduce flares, and consequently, hospitalizations for management of acute symptoms are expected to decrease[31–33].

On the other hand, the increased hospitalizations can be explained by more patients being diagnosed, given that the incidence of IBD rising[1,34,35]. A global, population-based study using the Organization for Economic Co-operation and Development database found high IBD hospitalization rates in Western countries that were stabilizing or decreasing over a 25 year period, and conversely, low IBD hospitalization rates in newly industrialized countries that were increasing over time[36]. Counts of hospitalizations could also be affected by patients requiring readmission. Early and late readmissions are common in this patient population. Fifty percent of 30-d readmissions for IBD are due to acute flares, and unplanned admissions rates are up to 39% at 1 year from initial hospitalization[37,38]. These readmissions come from the full spectrum of IBD-related morbidity including bowel obstruction, pain control, complications from surgery, and presence of comorbid conditions[39,40]. While IBD therapeutic agents are safe, there is also data suggesting increased hospitalizations may be due to side effects and complications related to the medication, which then may be categorized as IBD-related admissions. For example, it is well established that patients on these medications are at increased risk for serious or opportunistic infections, an annual incidence ranging from 1.1%-2.2%, especially within the first 90 d of initiating treatment[41,42].

As a result, classification of hospitalizations into elective *vs* emergent may provide insight on disease control. A United Kingdom study calculating age- and sex- adjusted rates of IBD-related hospitalizations found a significant increase in hospitalizations over time with a broad shift from emergency care to shorter elective hospital stays in the setting of increased cytokine infusion rates[43]. Alternatively, an analysis of Washington State IBD-related hospitalizations revealed fewer than one in four hospitalizations for IBD were elective, and the vast majority were related to surgery, whereas emergent admissions were primarily for medical management.[44] These different practice patterns may suggest that perhaps variation can be explained by regional differences, but also point to a gap in clinical data to match the population.

**impact of endoscopy on hospitalization**

The contribution of endoscopy to hospitalization for IBD has been evolving. Endoscopy plays an important role in all facets of IBD care including initial diagnosis, assessing response to therapy, neoplasia and post-surgical surveillance and therapeutic interventions. Despite this, the proportion of lower endoscopies performed during inpatient admissions for CD has decreased significantly over the past several decades, while this has been stable in patients with UC (6.3% to 3.7% for CD and 18.4% to 17.6% for UC)[44]. One reason for this change could be improved disease control in outpatient setting, including the introduction of biologics. The role of diagnostic endoscopy in IBD will likely remain essential over time with studies showing improved outcomes when medical treatment is targeted for endoscopic remission[45]. Most endoscopic procedures are done in the outpatient setting and have the potential to prevent hospitalizations through early detection of disease progression or neoplasia in the setting of IBD. Population-level data demonstrating this impact, to date, is lacking.

Diagnostic endoscopy is also used during hospital admissions for several reasons. In addition to its diagnostic role in differentiating CD from ulcerative colitis, endoscopy is recommended in the inpatient setting to assess initial disease severity and response to therapy or co-infection in patients with acute severe UC or to manage complications in patients with stricturing CD[46]. Additionally, a study analyzing UC-related hospitalizations in the Nationwide Inpatient Sample database found that early sigmoidoscopy or colonoscopy, defined as within 2 days of admission, was associated with lower in-hospital mortality, costs, and length of stay compared to delayed endoscopy[47].

In addition to diagnosis, therapeutic endoscopy is playing an increasingly important role in IBD and IBD-related complications. Examples of this include stricture and fistula evaluation and treatment. Short, straight-angled strictures (commonly ileocolonic or ileal pouch anastomotic strictures) have been shown to be amenable to endoscopic balloon dilation and can improve symptoms and replace or delay surgery. Needle-knife stricturotomy (NKSt) and self-expanding metal stent placement are under investigation[48]. Endoscopic ultrasound has been shown to be as effective in evaluating peri-anal fistulae as exam under anesthesia or magnetic resonance imaging. Endoscopy with endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) is an accepted treatment modality for patients with focal IBD-related neoplasia[49,50]. It is important to note that the majority of these procedures are done on an outpatient basis, but may have an important effect on hospitalizations. A study evaluating efficacy and safety of NKSt showed that only 15.3% of patients needed stricture-related surgery after almost one year[51]. More data will need to be collected to assess the impacts of interventional IBD treatments and hospitalization rates.

**impact of surgery on hospitalizations**

Historically, it has been reported that 30% of patients with UC and 70% of patients with CD will ultimately require surgical intervention within 10 years of diagnosis[52,53]. Over the past few decades, the risk of needing surgery has decreased, with 10-year estimated risk among patients with UC being 10%-16% and 45%-50% for CD[54–56]. However, surgery still accounts for at least 40% of overall hospitalizations[12]. More recently, the overall rate of IBD patients requiring surgery has remained relatively stable with a shift towards more elective, rather than urgent or emergent, operations[57–59]. Thus, we may not see that expected reduction in hospitalizations that we were anticipating with the advent of advanced therapeutics.

Indications for emergent surgery for UC include perforation, life-threatening hemorrhage, toxic megacolon, and fulminant colitis whereas surgical management in the emergency setting for CD is observed for the fistulizing and stricturing phenotypes causing intestinal obstruction, bleeding, or abscess[60]. In both patient populations, emergency intestinal resections carry higher morbidity and mortality compared to elective cases[61]. Fortunately, the rates of emergency surgery for both UC and CD have been declining[58,59,62–64]. With this shift towards elective surgeries, operative strategies have also been affected. For instance, in UC, options include staged restorative surgery. Recent studies have reported a shift towards total abdominal colectomy rather than total proctocolectomy as the most commonly performed index operation and more ileoanal pouches constructed at a subsequent operation[65,66]. In patients with CD, there have been fewer emergency stomas created[67].

Elective IBD surgery is often performed for medically refractory disease, complications, and in UC specifically, for curative intent. The rates of elective procedures have been increasing[59], as has optimization of elective surgery with shifts towards minimally invasive surgery and enhanced recovery after surgery[68–70]. The use of laparoscopic and robotic-assisted colon resections and enhanced recovery pathways decrease hospital length of stay and are cost-effective at the population level[71–73]. Furthermore, utilization of newer techniques such as Kono-S anastomosis and mesentery exclusion for ileocolic CD have shown favorable results of decreased rates of disease recurrence[74–77], and may result ultimately in fewer operations over a patient’s lifetime. Future studies are needed to assess long-term outcomes and the need for subsequent operations that may ultimately lead to standardization of these techniques in the elective setting.

While emergent and elective surgeries have had distinct trends over the past two decades, the drivers leading to overall variable surgery rates remain poorly understood. Rates of colectomy have varied based on geographic region, time period, and extent of disease. With the increasing use of biologic agents and immunomodulators, several time-trend population-based studies have attempted to determine if there is a correlation between these drugs and need for surgery. Early studies have found relatively stable surgery rates in patients with CD with the introduction of infliximab[78]. More recently, some researchers demonstrated a decrease in surgeries for medically refractory CD during a time period before and after the induction of infliximab and adalimumab, suggesting that declining trends also involve other factors. Conversely, studies investigating trends of colectomy in patients with ulcerative colitis have found decreasing rates in patients undergoing treatment with infliximab or other biologics[79–81], but may have higher postoperative morbidity and mortality[66,82,83]. Additionally, these therapeutic agents may instead have a role in delaying surgery, rather than reducing the overall number of procedures, which is also supported by the shift from emergent to elective operations[64,84]. The changes in prevalence of modifiable risk factors affecting IBD, such as smoking and obesity, may also be contributing to surgical rates[85,86].

**impact of high volume IBD-care on hospitalizations**

With the increasing number of patients afflicted by this disease coupled with the increased complexity for inpatient and outpatient treatment, there is mounting data demonstrating improved outcomes for patients when care is specialized (Table 1). Multidisciplinary teams (MDTs) exist in the United States and abroad and the makeup of teams varies from institution to institution. Committees of expert opinion have met and made reasonable recommendations for what should comprise an IBD MDT[87]. Colectomies performed by high-volume IBD colorectal surgeons show better outcomes, even when adjusted for volume of cases at their institutions[88,89]. In one study, IBD-specialized gastroenterologists have shown tighter adherence to guidelines, in general[90]. Inpatient IBD care models have found that a personalized, therapeutic approach led by an inpatient IBD gastroenterologist may lead to greater rates of remission and earlier surgical referral and intervention[91]. Increased emphasis has been placed on limiting narcotic use, antibiotic stewardship, enteral nutrition, and venous thromboembolism (VTE) prophylaxis[92–94]. The effects of VTE prophylaxis for IBD patients on hospitalization cannot be overstated as this population has an estimated 2-3 fold increase in incidence of VTE compared to normal population[95,96] as well as higher mortality with VTE[1]. Gastroenterologists with significant IBD experience (greater than 50% of patient volume with IBD) are more likely to provide anticoagulation for hospitalized patients[97], something that is recommended by multiple gastroenterology societies[98,99].

Fragmentation of care, however, appears to be an important risk factor for worse outcomes[100,101]. This may be the case because different institutions may not share documentation, have the same resources or expertise with IBD or directly communicate with a patient’s primary gastroenterologist during an admission. Considering these possibilities, it should not be a surprise that fragmented care is associated with worse outcomes. To overcome this obstacle, developing more specialized IBD centers as well as improving communication between providers who care for IBD should be considered.

Regionalization may also impact hospitalization and IBD outcomes. Hospitals with high volume IBD cases, defined as greater than 150 annual IBD-related hospitalizations, have lower in-hospital mortality among patients requiring surgery and shorter post-operative stays[102]. While the care complexities related to IBD may make it a suitable target for regionalization, barriers to implementation include fragmentation, increased travel distance, and patient socioeconomic status. For example, a single-site study showed direct correlation between distance patients live from specialty center and outcomes including need for surgery, biologics and immunomodulators after follow-up period[103]. Additionally, rural IBD patients have greater rates of emergency department visits and hospitalizations compared to urban IBD patients[104]. These are important factors to consider and may aid in the shared decision-making between patients and providers.

**CONCLUSION**

An understanding of the burden of IBD hospitalizations is important for cost containment and disease management. Population-based studies provide the best reflection of real-world strategies and have shown that there has been an overall increase in IBD hospitalization rates and decrease in endoscopy and emergency surgery. IBD hospitalization is impacted by disease epidemiology as well as medical, endoscopic, and surgical treatment. Improved inpatient care for IBD patients over time may comprise of the increased utilization of disease modifying agents in the outpatient setting, assessment of short and long-term outcomes of elective surgeries, and early access to high-volume IBD care.

**REFERENCES**

1 **Molodecky NA**, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; **142**: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]

2 **GBD 2017 Inflammatory Bowel Disease Collaborators**. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol* 2020; **5**: 17-30 [PMID: 31648971 DOI: 10.1016/S2468-1253(19)30333-4]

3 **Targan SR**, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *N Engl J Med* 1997; **337**: 1029-1035 [PMID: 9321530 DOI: 10.1056/nejm199710093371502]

4 **Hanauer SB**, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet* 2002; **359**: 1541-1549 [PMID: 12047962 DOI: 10.1016/S0140-6736(02)08512-4]

5 **Rutgeerts P**, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2005; **353**: 2462-2476 [PMID: 16339095 DOI: 10.1056/nejmoa050516]

6 **Herrinton LJ**, Liu L, Fireman B, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Abramson O, Altschuler A, Perry GS. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. *Gastroenterology* 2009; **137**: 502-511 [PMID: 19445944 DOI: 10.1053/j.gastro.2009.04.063]

7 **Jeuring SF**, van den Heuvel TR, Liu LY, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, Oostenbrug LE, Masclee AA, Jonkers DM, Pierik MJ. Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. *Am J Gastroenterol* 2017; **112**: 325-336 [PMID: 27922024 DOI: 10.1038/ajg.2016.524]

8 **Murthy SK**, Begum J, Benchimol EI, Bernstein CN, Kaplan GG, McCurdy JD, Singh H, Targownik L, Taljaard M. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. *Gut* 2020; **69**: 274-282 [PMID: 31196874 DOI: 10.1136/gutjnl-2019-318440]

9 **Odes S**, Vardi H, Friger M, Wolters F, Russel MG, Riis L, Munkholm P, Politi P, Tsianos E, Clofent J, Vermeire S, Monteiro E, Mouzas I, Fornaciari G, Sijbrandij J, Limonard C, Van Zeijl G, O'morain C, Moum B, Vatn M, Stockbrugger R; European Collaborative Study on Inflammatory Bowel Disease. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. *Gastroenterology* 2006; **131**: 719-728 [PMID: 16952541 DOI: 10.1053/j.gastro.2006.05.052]

10 **van Langenberg DR**, Simon SB, Holtmann GJ, Andrews JM. The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: a single metropolitan Australian center experience. *J Crohns Colitis* 2010; **4**: 413-421 [PMID: 21122537 DOI: 10.1016/j.crohns.2010.01.004]

11 **Lichtenstein GR**, Shahabi A, Seabury SA, Lakdawalla DN, Espinosa OD, Green S, Brauer M, Baldassano RN. Lifetime Economic Burden of Crohn's Disease and Ulcerative Colitis by Age at Diagnosis. *Clin Gastroenterol Hepatol* 2020; **18**: 889-897.e10 [PMID: 31326606 DOI: 10.1016/j.cgh.2019.07.022]

12 **Kappelman MD**, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, Finkelstein JA. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. *Gastroenterology* 2008; **135**: 1907-1913 [PMID: 18854185 DOI: 10.1053/j.gastro.2008.09.012]

13 **Longobardi T**, Jacobs P, Bernstein CN. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. *Am J Gastroenterol* 2004; **99**: 650-655 [PMID: 15089897 DOI: 10.1111/j.1572-0241.2004.04132.x]

14 **Truelove SC**, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J* 1955; **2**: 1041-1048 [PMID: 13260656 DOI: 10.1136/bmj.2.4947.1041]

15 **Truelove SC**, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. *Lancet* 1974; **1**: 1067-1070 [PMID: 4135487 DOI: 10.1016/S0140-6736(74)90552-2]

16 **Ford AC**, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, Moayyedi P. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol* 2011; **106**: 590-9; quiz 600 [PMID: 21407179 DOI: 10.1038/ajg.2011.70]

17 **Benchimol EI**, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. *Cochrane Database Syst Rev* 2008: CD006792 [PMID: 18425970 DOI: 10.1002/14651858.CD006792.pub2]

18 **Ramadas AV**, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. *Gut* 2010; **59**: 1200-1206 [PMID: 20650924 DOI: 10.1136/gut.2009.202101]

19 **Selinger CP**, Parkes GC, Bassi A, Fogden E, Hayee B, Limdi JK, Ludlow H, McLaughlin S, Patel P, Smith M, Raine T. A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2017; **46**: 964-973 [PMID: 28949018 DOI: 10.1111/apt.14334]

20 **van der Valk ME**, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk CJ, Vermeijden JR, Siersema PD, van Oijen MG, Oldenburg B; COIN study group and the Dutch Initiative on Crohn and Colitis. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. *Gut* 2014; **63**: 72-79 [PMID: 23135759 DOI: 10.1136/gutjnl-2012-303376]

21 **Xu J**, Tang M, Shen J. Trends and Factors Affecting Hospitalization Costs in Patients with Inflammatory Bowel Disease: A Two-Center Study over the Past Decade. *Gastroenterol Res Pract* 2013; **2013**: 267630 [PMID: 24307891 DOI: 10.1155/2013/267630]

22 **Kelso M**, Weideman RA, Cipher DJ, Feagins LA. Factors Associated With Length of Stay in Veterans With Inflammatory Bowel Disease Hospitalized for an Acute Flare. *Inflamm Bowel Dis* 2017; **24**: 5-11 [PMID: 29272483 DOI: 10.1093/ibd/izx020]

23 **Ha C**, Maser EA, Kornbluth A. Clinical presentation and outcomes of inflammatory bowel disease patients admitted to the intensive care unit. *J Clin Gastroenterol* 2013; **47**: 485-490 [PMID: 23388843 DOI: 10.1097/MCG.0b013e318275d981]

24 **Malhotra A**, Mandip KC, Shaukat A, Rector T. All-cause hospitalizations for inflammatory bowel diseases: Can the reason for admission provide information on inpatient resource use? A study from a large veteran affairs hospital. *Mil Med Res* 2016; **3**: 28 [PMID: 27602233 DOI: 10.1186/s40779-016-0098-x]

25 **Nguyen GC**, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. *Am J Gastroenterol* 2008; **103**: 1443-1450 [PMID: 18513271 DOI: 10.1111/j.1572-0241.2007.01780.x]

26 **Rocha R**, Sousa UH, Reis TLM, Santana GO. Nutritional status as a predictor of hospitalization in inflammatory bowel disease: A review. *World J Gastrointest Pharmacol Ther* 2019; **10**: 50-56 [PMID: 30891328 DOI: 10.4292/wjgpt.v10.i2.50]

27 **Sonnenberg A**. Age distribution of IBD hospitalization. *Inflamm Bowel Dis* 2010; **16**: 452-457 [PMID: 19714765 DOI: 10.1002/ibd.21058]

28 **Nguyen GC**, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. *Inflamm Bowel Dis* 2007; **13**: 1529-1535 [PMID: 17828784 DOI: 10.1002/ibd.20250]

29 **Bewtra M**, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. *Clin Gastroenterol Hepatol* 2007; **5**: 597-601 [PMID: 17382602 DOI: 10.1016/j.cgh.2007.01.015]

30 **Ananthakrishnan AN**, McGinley EL, Binion DG, Saeian K. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. *J Gastrointest Surg* 2011; **15**: 267-276 [PMID: 21108015 DOI: 10.1007/s11605-010-1396-3]

31 **Feagan BG**, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. *Gastroenterology* 2008; **135**: 1493-1499 [PMID: 18848553 DOI: 10.1053/j.gastro.2008.07.069]

32 **Mao EJ**, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. *Aliment Pharmacol Ther* 2017; **45**: 3-13 [PMID: 27862107 DOI: 10.1111/apt.13847]

33 **Perera S**, Yang S, Stott-Miller M, Brady J. Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease. *J Health Econ Outcomes Res* 2018; **6**: 96-112 [PMID: 32685575 DOI: 10.36469/9791]

34 **Kaplan GG**. The global burden of IBD: from 2015 to 2025. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 720-727 [PMID: 26323879 DOI: 10.1038/nrgastro.2015.150]

35 **Jung YS**, Han M, Kim WH, Park S, Cheon JH. Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011-2014: A Nationwide Population-Based Study. *Dig Dis Sci* 2017; **62**: 2102-2112 [PMID: 28593437 DOI: 10.1007/s10620-017-4640-9]

36 **King JA**, Underwood FE, Panaccione N, Quan J, Windsor JW, Kotze PG, Ng SC, Ghosh S, Lakatos PL, Jess T, Panaccione R, Seow CH, Ben-Horin S, Burisch J, Colombel JF, Loftus EV Jr, Gearry R, Halfvarson J, Kaplan GG. Trends in hospitalisation rates for inflammatory bowel disease in western *vs* newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. *Lancet Gastroenterol Hepatol* 2019; **4**: 287-295 [PMID: 30765267 DOI: 10.1016/S2468-1253(19)30013-5]

37 **Hazratjee N**, Agito M, Lopez R, Lashner B, Rizk MK. Hospital readmissions in patients with inflammatory bowel disease. *Am J Gastroenterol* 2013; **108**: 1024-1032 [PMID: 23820989 DOI: 10.1038/ajg.2012.343]

38 **Mudireddy P**, Scott F, Feathers A, Lichtenstein GR. Inflammatory Bowel Disease: Predictors and Causes of Early and Late Hospital Readmissions. *Inflamm Bowel Dis* 2017; **23**: 1832-1839 [PMID: 28858068 DOI: 10.1097/MIB.0000000000001242]

39 **Allegretti JR**, Borges L, Lucci M, Chang M, Cao B, Collins E, Vogel B, Arthur E, Emmons D, Korzenik JR. Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2015; **21**: 2583-2589 [PMID: 26244647 DOI: 10.1097/MIB.0000000000000537]

40 **Barnes EL**, Kochar B, Long MD, Kappelman MD, Martin CF, Korzenik JR, Crockett SD. Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database. *Inflamm Bowel Dis* 2017; **23**: 875-881 [PMID: 28426473 DOI: 10.1097/MIB.0000000000001121]

41 **Nyboe Andersen N**, Pasternak B, Friis-Møller N, Andersson M, Jess T. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. *BMJ* 2015; **350**: h2809 [PMID: 26048617 DOI: 10.1136/bmj.h2809]

42 **Kirchgesner J**, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. *Gastroenterology* 2018; **155**: 337-346.e10 [PMID: 29655835 DOI: 10.1053/j.gastro.2018.04.012]

43 **Ahmad A**, Laverty AA, Alexakis C, Cowling T, Saxena S, Majeed A, Pollok RCG. Changing nationwide trends in endoscopic, medical and surgical admissions for inflammatory bowel disease: 2003-2013. *BMJ Open Gastroenterol* 2018; **5**: e000191 [PMID: 29607052 DOI: 10.1136/bmjgast-2017-000191]

44 **Soriano C,** Chiorean MV, Kaplan JA, Selva DL, Lord JD, Moonka R, Zisman TL, Simianu VV. Understanding the Centralization of Inflammatory Bowel Disease Hospitalizations and Operations in Washington State. *Gastroenterology* 2021; **160**: S-872 [DOI: 10.1016/S0016-5085(21)02812-2]

45 **Peyrin-Biroulet L**, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *Am J Gastroenterol* 2015; **110**: 1324-1338 [PMID: 26303131 DOI: 10.1038/ajg.2015.233]

46 **Lewin S**, Velayos FS. Day-by-Day Management of the Inpatient With Moderate to Severe Inflammatory Bowel Disease. *Gastroenterol Hepatol (N Y)* 2020; **16**: 449-457 [PMID: 34035752]

47 **Macaron C**, Lopez R, Pai RK, Burke CA. Expression of Annexin A10 in Serrated Polyps Predicts the Development of Metachronous Serrated Polyps. *Clin Transl Gastroenterol* 2016; **7**: e205 [PMID: 27906163 DOI: 10.1038/ctg.2016.60]

48 **Spiceland CM**, Lodhia N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment. *World J Gastroenterol* 2018; **24**: 4014-4020 [PMID: 30254405 DOI: 10.3748/wjg.v24.i35.4014]

49 **ASGE Technology Committee**, Kantsevoy SV, Adler DG, Conway JD, Diehl DL, Farraye FA, Kwon R, Mamula P, Rodriguez S, Shah RJ, Wong Kee Song LM, Tierney WM. Endoscopic mucosal resection and endoscopic submucosal dissection. *Gastrointest Endosc* 2008; **68**: 11-18 [PMID: 18577472 DOI: 10.1016/j.gie.2008.01.037]

50 **Wang J**, Zhang XH, Ge J, Yang CM, Liu JY, Zhao SL. Endoscopic submucosal dissection *vs* endoscopic mucosal resection for colorectal tumors: a meta-analysis. *World J Gastroenterol* 2014; **20**: 8282-8287 [PMID: 25009404 DOI: 10.3748/wjg.v20.i25.8282]

51 **Lan N**, Shen B. Endoscopic Stricturotomy with Needle Knife in the Treatment of Strictures from Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2017; **23**: 502-513 [PMID: 28296818 DOI: 10.1097/MIB.0000000000001044]

52 **Langholz E**, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. *Gastroenterology* 1994; **107**: 3-11 [PMID: 8020674 DOI: 10.1016/0016-5085(94)90054-X]

53 **Bernell O**, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. *Ann Surg* 2000; **231**: 38-45 [PMID: 10636100 DOI: 10.1097/00000658-200001000-00006]

54 **Frolkis AD**, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, Frolkis T, Barkema HW, Rioux KP, Panaccione R, Ghosh S, Wiebe S, Kaplan GG. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. *Gastroenterology* 2013; **145**: 996-1006 [PMID: 23896172 DOI: 10.1053/j.gastro.2013.07.041]

55 **Targownik LE**, Kaplan GG, Witt J, Bernstein CN, Singh H, Tennakoon A, Aviña Zubieta A, Coward SB, Jones J, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN, Benchimol EI. Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. *Am J Gastroenterol* 2020; **115**: 128-137 [PMID: 31895723 DOI: 10.14309/ajg.0000000000000503]

56 **Bouguen G**, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? *Gut* 2011; **60**: 1178-1181 [PMID: 21610273 DOI: 10.1136/gut.2010.234617]

57 **Lazarev M**, Ullman T, Schraut WH, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center. *Inflamm Bowel Dis* 2010; **16**: 830-835 [PMID: 19798731 DOI: 10.1002/ibd.21118]

58 **Ma C**, Moran GW, Benchimol EI, Targownik LE, Heitman SJ, Hubbard JN, Seow CH, Novak KL, Ghosh S, Panaccione R, Kaplan GG. Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. *Am J Gastroenterol* 2017; **112**: 1840-1848 [PMID: 29087396 DOI: 10.1038/ajg.2017.394]

59 **Lowe SC**, Sauk JS, Limketkai BN, Kwaan MR. Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy. *J Gastrointest Surg* 2021; **25**: 211-219 [PMID: 33140318 DOI: 10.1007/s11605-020-04832-y]

60 **Berg DF**, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. *Am J Surg* 2002; **184**: 45-51 [PMID: 12135718 DOI: 10.1016/S0002-9610(02)00879-6]

61 **Tøttrup A**, Erichsen R, Sværke C, Laurberg S, Srensen HT. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. *BMJ Open* 2012; **2**: e000823 [PMID: 22492386 DOI: 10.1136/bmjopen-2012-000823]

62 **Ghoz H**, Kesler A, Hoogenboom SA, Gavi F, Brahmbhatt B, Cangemi J, Kröner PT. Decreasing Colectomy Rates in Ulcerative Colitis in the Past Decade: Improved Disease Control? *J Gastrointest Surg* 2020; **24**: 270-277 [PMID: 31797257 DOI: 10.1007/s11605-019-04474-9]

63 **Kayal M**, Saha A, Poojary P, Paramsothy S, Hirten R, Cohen L, Gallinger Z, Mehandru S, Cho J, Greenstein A, Nadkarni G, Dubinsky MC, Colombel JF, Cohen B, Ungaro R. Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study. *Int J Colorectal Dis* 2019; **34**: 1771-1779 [PMID: 31512019 DOI: 10.1007/s00384-019-03375-2]

64 **Rajan R**, Trinder MW, Lo J, Theophilus M. Assessing the efficacy of TNF-alpha inhibitors in preventing emergency and emergent colectomies. *JGH Open* 2020; **4**: 140-144 [PMID: 32280756 DOI: 10.1002/jgh3.12229]

65 **Geltzeiler CB**, Lu KC, Diggs BS, Deveney KE, Keyashian K, Herzig DO, Tsikitis VL. Initial surgical management of ulcerative colitis in the biologic era. *Dis Colon Rectum* 2014; **57**: 1358-1363 [PMID: 25380000 DOI: 10.1097/DCR.0000000000000236]

66 **Ellis MC**, Diggs BS, Vetto JT, Herzig DO. Trends in the surgical treatment of ulcerative colitis over time: increased mortality and centralization of care. *World J Surg* 2011; **35**: 671-676 [PMID: 21165620 DOI: 10.1007/s00268-010-0910-9]

67 **Ma C**, Almutairdi A, Tanyingoh D, Seow CH, Novak KL, Lu C, Panaccione R, Kaplan GG, Kotze PG. Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis. *Colorectal Dis* 2019; **21**: 1279-1287 [PMID: 31206974 DOI: 10.1111/codi.14731]

68 **Sica GS**, Biancone L. Surgery for inflammatory bowel disease in the era of laparoscopy. *World J Gastroenterol* 2013; **19**: 2445-2448 [PMID: 23674844 DOI: 10.3748/wjg.v19.i16.2445]

69 **Mege D**, Garrett K, Milsom J, Sonoda T, Michelassi F. Changing trends in surgery for abdominal Crohn's disease. *Colorectal Dis* 2019; **21**: 200-207 [PMID: 30341932 DOI: 10.1111/codi.14450]

70 **Gaglani T**, Davis CH, Bailey HR, Cusick MV. Trends and Outcomes for Minimally Invasive Surgery for Inflammatory Bowel Disease. *J Surg Res* 2019; **235**: 303-307 [PMID: 30691810 DOI: 10.1016/j.jss.2018.09.075]

71 **Carmichael JC**, Keller DS, Baldini G, Bordeianou L, Weiss E, Lee L, Boutros M, McClane J, Feldman LS, Steele SR. Clinical Practice Guidelines for Enhanced Recovery After Colon and Rectal Surgery From the American Society of Colon and Rectal Surgeons and Society of American Gastrointestinal and Endoscopic Surgeons. *Dis Colon Rectum* 2017; **60**: 761-784 [PMID: 28682962 DOI: 10.1097/DCR.0000000000000883]

72 **Liska D,** Bora Cengiz T, Novello M, Aiello A, Stocchi L, Hull TL, Steele SR, Delaney CP, Holubar SD. Do Patients with Inflammatory Bowel Disease Benefit from an Enhanced Recovery Pathway? In: Inflammatory Bowel Diseases. Oxford University Press, 2020: 476-483

73 **Simianu VV**, Gaertner WB, Kuntz K, Kwaan MR, Lowry AC, Madoff RD, Jensen CC. Cost-effectiveness Evaluation of Laparoscopic Versus Robotic Minimally Invasive Colectomy. *Ann Surg* 2020; **272**: 334-341 [PMID: 32675547 DOI: 10.1097/SLA.0000000000003196]

74 **Kono T**, Ashida T, Ebisawa Y, Chisato N, Okamoto K, Katsuno H, Maeda K, Fujiya M, Kohgo Y, Furukawa H. A new antimesenteric functional end-to-end handsewn anastomosis: surgical prevention of anastomotic recurrence in Crohn's disease. *Dis Colon Rectum* 2011; **54**: 586-592 [PMID: 21471760 DOI: 10.1007/DCR.0b013e318208b90f]

75 **Kono T**, Fichera A, Maeda K, Sakai Y, Ohge H, Krane M, Katsuno H, Fujiya M. Kono-S Anastomosis for Surgical Prophylaxis of Anastomotic Recurrence in Crohn's Disease: an International Multicenter Study. *J Gastrointest Surg* 2016; **20**: 783-790 [PMID: 26696531 DOI: 10.1007/s11605-015-3061-3]

76 **Luglio G**, Rispo A, Imperatore N, Giglio MC, Amendola A, Tropeano FP, Peltrini R, Castiglione F, De Palma GD, Bucci L. Surgical Prevention of Anastomotic Recurrence by Excluding Mesentery in Crohn's Disease: The SuPREMe-CD Study - A Randomized Clinical Trial. *Ann Surg* 2020; **272**: 210-217 [PMID: 32675483 DOI: 10.1097/SLA.0000000000003821]

77 **Coffey CJ**, Kiernan MG, Sahebally SM, Jarrar A, Burke JP, Kiely PA, Shen B, Waldron D, Peirce C, Moloney M, Skelly M, Tibbitts P, Hidayat H, Faul PN, Healy V, O'Leary PD, Walsh LG, Dockery P, O'Connell RP, Martin ST, Shanahan F, Fiocchi C, Dunne CP. Inclusion of the Mesentery in Ileocolic Resection for Crohn's Disease is Associated With Reduced Surgical Recurrence. *J Crohns Colitis* 2018; **12**: 1139-1150 [PMID: 29309546 DOI: 10.1093/ecco-jcc/jjx187]

78 **Jones DW**, Finlayson SR. Trends in surgery for Crohn's disease in the era of infliximab. *Ann Surg* 2010; **252**: 307-312 [PMID: 20585239 DOI: 10.1097/SLA.0b013e3181e61df5]

79 **Sandborn WJ**, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. *Gastroenterology* 2009; **137**: 1250-60; quiz 1520 [PMID: 19596014 DOI: 10.1053/j.gastro.2009.06.061]

80 **Parragi L**, Fournier N, Zeitz J, Scharl M, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group . Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. *J Crohns Colitis* 2018; **12**: 811-818 [PMID: 29617750 DOI: 10.1093/ecco-jcc/jjy040]

81 **Barnes EL**, Jiang Y, Kappelman MD, Long MD, Sandler RS, Kinlaw AC, Herfarth HH. Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis. *Inflamm Bowel Dis* 2020; **26**: 1225-1231 [PMID: 31634390 DOI: 10.1093/ibd/izz247]

82 **Mor IJ**, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. *Dis Colon Rectum* 2008; **51**: 1202-7; discussion 1207-10 [PMID: 18536964 DOI: 10.1007/s10350-008-9364-7]

83 **Abelson JS**, Michelassi F, Mao J, Sedrakyan A, Yeo H. Higher Surgical Morbidity for Ulcerative Colitis Patients in the Era of Biologics. *Ann Surg* 2018; **268**: 311-317 [PMID: 28448381 DOI: 10.1097/SLA.0000000000002275]

84 **Aratari A**, Papi C, Clemente V, Moretti A, Luchetti R, Koch M, Capurso L, Caprilli R. Colectomy rate in acute severe ulcerative colitis in the infliximab era. *Dig Liver Dis* 2008; **40**: 821-826 [PMID: 18472316 DOI: 10.1016/j.dld.2008.03.014]

85 **Cosnes J**. Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD. *Dig Dis* 2010; **28**: 411-417 [PMID: 20926865 DOI: 10.1159/000320395]

86 **Kuenzig ME**, Lee SM, Eksteen B, Seow CH, Barnabe C, Panaccione R, Kaplan GG. Smoking influences the need for surgery in patients with the inflammatory bowel diseases: a systematic review and meta-analysis incorporating disease duration. *BMC Gastroenterol* 2016; **16**: 143 [PMID: 28003021 DOI: 10.1186/s12876-016-0555-8]

87 **Louis E**, Dotan I, Ghosh S, Mlynarsky L, Reenaers C, Schreiber S. Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations. *J Crohns Colitis* 2015; **9**: 685-691 [PMID: 25987349 DOI: 10.1093/ecco-jcc/jjv085]

88 **Callahan MA**, Christos PJ, Gold HT, Mushlin AI, Daly JM. Influence of surgical subspecialty training on in-hospital mortality for gastrectomy and colectomy patients. *Ann Surg* 2003; **238**: 629-36; discussion 636-9 [PMID: 14530734 DOI: 10.1097/01.sla.0000089855.96280.4a]

89 **Hicks CW**, Hodin RA, Bordeianou L. Semi-urgent surgery in hospitalized patients with severe ulcerative colitis does not increase overall J-pouch complications. *Am J Surg* 2014; **207**: 281-287 [PMID: 24112682 DOI: 10.1016/j.amjsurg.2013.06.006]

90 **Bilal M**, Singh S, Lee H, Khosa K, Khehra R, Clarke K. Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists. *Ann Gastroenterol* 2017; **30**: 192-196 [PMID: 28243040 DOI: 10.20524/aog.2016.0114]

91 **Law CC**, Sasidharan S, Rodrigues R, Nguyen DD, Sauk J, Garber J, Giallourakis C, Xavier R, Khalili H, Yajnik V, Ananthakrishnan AN. Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study. *Inflamm Bowel Dis* 2016; **22**: 2149-2157 [PMID: 27482978 DOI: 10.1097/MIB.0000000000000870]

92 **Cross RK**, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. *Am J Gastroenterol* 2005; **100**: 2225-2229 [PMID: 16181373 DOI: 10.1111/j.1572-0241.2005.00256.x]

93 **Ledder O**. Antibiotics in inflammatory bowel diseases: do we know what we're doing? *Transl Pediatr* 2019; **8**: 42-55 [PMID: 30881898 DOI: 10.21037/tp.2018.11.02]

94 **Triantafillidis JK**, Vagianos C, Papalois AE. The role of enteral nutrition in patients with inflammatory bowel disease: current aspects. *Biomed Res Int* 2015; **2015**: 197167 [PMID: 25793189 DOI: 10.1155/2015/197167]

95 **Yuhara H**, Steinmaus C, Corley D, Koike J, Igarashi M, Suzuki T, Mine T. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2013; **37**: 953-962 [PMID: 23550660 DOI: 10.1111/apt.12294]

96 **Murthy SK**, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. *Am J Gastroenterol* 2011; **106**: 713-718 [PMID: 21407182 DOI: 10.1038/ajg.2011.53]

97 **Tinsley A**, Naymagon S, Trindade AJ, Sachar DB, Sands BE, Ullman TA. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. *J Clin Gastroenterol* 2013; **47**: e1-e6 [PMID: 22476043 DOI: 10.1097/MCG.0b013e31824c0dea]

98 **Nguyen GC**, Bernstein CN, Bitton A, Chan AK, Griffiths AM, Leontiadis GI, Geerts W, Bressler B, Butzner JD, Carrier M, Chande N, Marshall JK, Williams C, Kearon C. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. *Gastroenterology* 2014; **146**: 835-848.e6 [PMID: 24462530 DOI: 10.1053/j.gastro.2014.01.042]

99 **Cheng K**, Faye AS. Venous thromboembolism in inflammatory bowel disease. *World J Gastroenterol* 2020; **26**: 1231-1241 [PMID: 32256013 DOI: 10.3748/wjg.v26.i12.1231]

100 **Cohen-Mekelburg S**, Rosenblatt R, Gold S, Shen N, Fortune B, Waljee AK, Saini S, Scherl E, Burakoff R, Unruh M. Fragmented Care is Prevalent Among Inflammatory Bowel Disease Readmissions and is Associated With Worse Outcomes. *Am J Gastroenterol* 2019; **114**: 276-290 [PMID: 30420634 DOI: 10.1038/s41395-018-0417-9]

101 **Warren LR**, Clarke JM, Arora S, Barahona M, Arebi N, Darzi A. Transitions of care across hospital settings in patients with inflammatory bowel disease. *World J Gastroenterol* 2019; **25**: 2122-2132 [PMID: 31114138 DOI: 10.3748/wjg.v25.i17.2122]

102 **Ananthakrishnan AN**, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. *Am J Gastroenterol* 2008; **103**: 2789-2798 [PMID: 18684184 DOI: 10.1111/j.1572-0241.2008.02054.x]

103 **Borren NZ**, Conway G, Tan W, Andrews E, Garber JJ, Yajnik V, Ananthakrishnan AN. Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2017; **23**: 1234-1239 [PMID: 28520589 DOI: 10.1097/MIB.0000000000001133]

104 **Benchimol EI**, Kuenzig ME, Bernstein CN, Nguyen GC, Guttmann A, Jones JL, Potter BK, Targownik LE, Catley CA, Nugent ZJ, Tanyingoh D, Mojaverian N, Underwood FE, Siddiq S, Otley AR, Bitton A, Carroll MW, deBruyn JC, Dummer TJ, El-Matary W, Griffiths AM, Jacobson K, Leddin D, Lix LM, Mack DR, Murthy SK, Peña-Sánchez JN, Singh H, Kaplan GG; Canadian Gastro-Intestinal Epidemiology Consortium. Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. *Clin Epidemiol* 2018; **10**: 1613-1626 [PMID: 30519110 DOI: 10.2147/CLEP.S178056]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest. The views expressed are those of the author(s) and do not reflect the official policy of the Department of the Army, the Department of Defense or the U.S. Government.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** March 19, 2021

**First decision:** May 4, 2021

**Article in press:** August 12, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Druvefors E, Wan QQ, Xiao Y **S-Editor:** Ma YJ **L-Editor:** A **P-Editor:** Li X

**Table 1 Components of high-value inflammatory bowel disease care**

|  |  |  |
| --- | --- | --- |
| Component of IBD care | Outcome | Ref. |
| Availability of subspecialty surgeon | In-hospital mortality for patients undergoing colectomy is lower (2.4%) when performed by subspecialized surgeons when compared to those without subspecialty training (4.8%) after adjusting for hospital and surgeon volume as well as patient characteristics | Callahan *et al*[88] |
| Patient proximity to specialized IBD center | Need for surgery, immunomodulators and biologic therapy all significantly increased in patients who live furthest from a specialty IBD center | Borren *et al*[103] |
| Establishment of a specialized IBD unit | Patients treated in IBD specialty units found to have greater remission rates at 90 days, equal surgery rates (yet higher non-resection surgery rates at 30 d) and earlier initiation of high-dose biologic therapy when compared to non-specialized group | Law *et al*[91] |
| Fragmentation of care | Patients receiving fragmented care (i.e., readmission to non-index hospital) found to have larger in-hospital mortality | Cohen-Mekelburg *et al*[100] |

IBD: inflammatory bowel disease.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**